Drug intelligence / Profile preview

VRC-FLUDNA057-00-VP

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VRC-FLUDNA057-00-VP is an investigational DNA vaccine developed for the prevention of pandemic influenza caused by the 2009 H1N1 virus. It consists of a single plasmid DNA encoding the hemagglutinin (HA) protein from the A/California/09(H1N1) influenza strain. The vaccine is designed to induce an immune response against H1N1 by expressing the HA antigen in host cells, thereby stimulating both humoral and cellular immunity. The vaccine was evaluated in a Phase 1 clinical trial (VRC 308) conducted at the National Institutes of Health, Bethesda, MD, to assess its safety and immunogenicity in healthy adults[3].

Targets

H1 HA (Influenza A hemagglutinin H1)

Beyond the preview

Go deeper on VRC-FLUDNA057-00-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-FLUDNA057-00-VP.

Explore the full profile